Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 37

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 37
---
 the election of Mr.Olivier Samuel, Mr.Eran Lohan and Ms. Liora Oren as members of the Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary shareholders’ meeting. 11.To approve on an advisory basis the appointment of the new senior management of the Company, as follows: Mr.Ronen Twito (Executive Chairman and Chief Executive Officer), Prof. Michel Revel, MD, PhD (Chief Scientific Officer), Mr.Kfir Molakandov, PhD (Vice President Research and Development) and Mr.Ariel Revel, MD (Director of Medical Affairs). 12.1. (i) to approve a new maximum aggregate amount of CHF [•] (cash based compensation including all applicable social security contributions) for the fixed compensation of the Board of Directors, (ii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of CHF [•] (equity or equity linked instruments including all applicable social security contributions) for the compensation of Board of Directors and (iii) to approve the participation in the purchase of a run -offinsurance policy for the members of the Board of Directors, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the current term of office until the next Ordinary Shareholders Meeting. 12.2. (i) to approve the new maximum aggregate amount of CHF [•] (cash compensation including all applicable social security contributions) for the fixed compensation of the Company’s executive officers, (ii) to approve the new maximum aggregate amount of CHF [•] (cash compensation including all applicable social security contributions) for the variable compensation of the Company’s executive officers, (iii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of CHF [•] (equity or equity linked instruments including all applicable social security contributions) for the Company’s executive officers, and iv (iv) to approve the participation in the purchase of a run -offinsurance policy for the Company’s executive officers, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the financial year 2025. 13.To approve the CVR Agreement on an advisory basis. 14.To approve the conversion of outstanding options and restricted stock units, or the RSUs, issued by Kadimastem into equivalent securities with identical rights